News

SciBase resolves on a directed share issue of approximately SEK 11 million
The board of directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has today, in accordance with the intention published by the Company ...
Immutep Limited: Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases
Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kgThe substantial reduct ...